Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Oxford Nanopore Technologies PLC ( (GB:ONT) ) has shared an update.
Oxford Nanopore Technologies plc has announced the appointment of Francis Van Parys as the new Chief Executive Officer, effective March 2, 2026. Van Parys, who brings extensive experience from leading roles at Radiometer, Cytiva, and GE Healthcare, will succeed Gordon Sanghera, the company’s founding CEO. This leadership transition is expected to drive the next phase of growth for Oxford Nanopore, leveraging Van Parys’ expertise in scaling innovation-driven businesses. The company anticipates continued expansion and innovation under his leadership, aiming to enhance operational execution and deliver value to stakeholders.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £128.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Spark’s Take on GB:ONT Stock
According to Spark, TipRanks’ AI Analyst, GB:ONT is a Neutral.
The overall stock score of 51 reflects a combination of financial challenges and technical weaknesses, offset by positive earnings guidance and corporate governance initiatives. The company’s revenue growth and strategic focus on improving profitability are promising, but current financial and market conditions pose significant risks.
To see Spark’s full report on GB:ONT stock, click here.
More about Oxford Nanopore Technologies PLC
Oxford Nanopore Technologies plc is a company focused on developing a new generation of nanopore-based molecular sensing technology. Their platform is used for real-time, high-performance analysis of DNA and RNA, applicable in various fields such as healthcare, food, and agriculture. The technology is utilized in over 125 countries to study biological entities and diseases, including cancer.
Average Trading Volume: 1,801,957
Technical Sentiment Signal: Strong Sell
Current Market Cap: £1.2B
Learn more about ONT stock on TipRanks’ Stock Analysis page.